References
1. Liakoni E, Rätz Bravo AE, Krähenbühl S. Hepatotoxicity of New Oral
Anticoagulants (NOACs). Drug Saf. 2015;38(8):711-20.
2. Yeh CH, Hogg K, Weitz JI. Overview of the new oral anticoagulants:
opportunities and challenges. Arterioscler Thromb Vasc Biol.2015;35(5):1056-65.
3. Prins MH, Lensing AW, Bauersachs R, et al. Oral rivaroxaban versus
standard therapy for the treatment of symptomatic venous
thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized
studies. Thrombosis journal. 2013;11(1):21.
4. López-López JA, Sterne JAC, Thom HHZ, et al. Oral anticoagulants for
prevention of stroke in atrial fibrillation: systematic review, network
meta-analysis, and cost effectiveness analysis. Bmj.2017;359:j5058.
5. Elikowski W, Małek M, Skowroński M, Wróblewski D, Skrzywanek P,
Zawilska K. [Hemoptysis during concomitant treatment with rivaroxaban
and amiodarone in a patient with a history of pulmonary disease].Polski merkuriusz lekarski : organ Polskiego Towarzystwa
Lekarskiego. 2015;39(232):227-30.
6. Menendez D, Michel J. Hemopericardium with tamponade following
rivaroxaban administration and its attenuation by CYP3A4 inhibitors.Proceedings (Baylor University Medical Center). 2016;29(4):414-5.
7. Stöllberger C, Bastovansky A, Finsterer J. Fatal intracerebral
bleeding under rivaroxaban. International journal of cardiology.2015;201:110-2.
8. Lang D, Freudenberger C, Weinz C. In vitro metabolism of rivaroxaban,
an oral, direct factor Xa inhibitor, in liver microsomes and hepatocytes
of rats, dogs, and humans. Drug Metab Dispos. 2009;37(5):1046-55.
9. Weinz C, Schwarz T, Kubitza D, Mueck W, Lang D. Metabolism and
excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats,
dogs, and humans. Drug Metab Dispos. 2009;37(5):1056-64.
10. Dias C, Moore KT, Murphy J, et al. Pharmacokinetics,
Pharmacodynamics, and Safety of Single-Dose Rivaroxaban in Chronic
Hemodialysis. Am J Nephrol. 2016;43(4):229-36.
11. Gnoth MJ, Buetehorn U, Muenster U, Schwarz T, Sandmann S. In vitro
and in vivo P-glycoprotein transport characteristics of rivaroxaban.J Pharmacol Exp Ther. 2011;338(1):372-80.
12. Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with
drugs that share its elimination pathways: pharmacokinetic effects in
healthy subjects. Br J Clin Pharmacol. 2013;76(3):455-66.
13. EPAR. EU Risk Management Planhttps://wwwemaeuropaeu/en/medicines/human/EPAR/xarelto.2018;[Accessed June 09, 2018].
14. FDA. XareltoXarelto (Rivaroxaban) Product Informationhttps://wwwaccessdatafdagov/drugsatfda_docs/label/2020/202439s031,022406s035lblpdf#page=60.2020;[Accessed March 01, 2020].
15. Gelosa P, Castiglioni L, Tenconi M, et al. Pharmacokinetic drug
interactions of the non-vitamin K antagonist oral anticoagulants
(NOACs). Pharmacol Res. 2018;135:60-79.
16. Anand SS, Bosch J, Eikelboom JW, et al. Rivaroxaban with or without
aspirin in patients with stable peripheral or carotid artery disease: an
international, randomised, double-blind, placebo-controlled trial.Lancet. 2018;391(10117):219-29.
17. Stöllberger C, Zuntner G, Bastovansky A, Finsterer J. Cerebral
hemorrhage under rivaroxaban. International journal of
cardiology. 2013;167(6):e179-81.
18. Mueck W, Becka M, Kubitza D, Voith B, Zuehlsdorf M. Population model
of the pharmacokinetics and pharmacodynamics of rivaroxaban–an oral,
direct factor xa inhibitor–in healthy subjects. Int J Clin
Pharmacol Ther. 2007;45(6):335-44.
19. Ning J, Liu T, Dong P, et al. Molecular Design Strategy to Construct
the Near-Infrared Fluorescent Probe for Selectively Sensing Human
Cytochrome P450 2J2. J Am Chem Soc. 2019;141(2):1126-34.
20. Lin YS, Dowling AL, Quigley SD, et al. Co-regulation of CYP3A4 and
CYP3A5 and contribution to hepatic and intestinal midazolam metabolism.Mol Pharmacol. 2002;62(1):162-72.
21. Wolbold R, Klein K, Burk O, et al. Sex is a major determinant of
CYP3A4 expression in human liver. Hepatology. 2003;38(4):978-88.
22. Ohtsuki S, Schaefer O, Kawakami H, et al. Simultaneous absolute
protein quantification of transporters, cytochromes P450, and
UDP-glucuronosyltransferases as a novel approach for the
characterization of individual human liver: comparison with mRNA levels
and activities. Drug Metab Dispos. 2012;40(1):83-92.
23. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism:
regulation of gene expression, enzyme activities, and impact of genetic
variation. Pharmacol Ther. 2013;138(1):103-41.
24. Michaels S, Wang MZ. The revised human liver cytochrome P450 ”Pie”:
absolute protein quantification of CYP4F and CYP3A enzymes using
targeted quantitative proteomics. Drug Metab Dispos.2014;42(8):1241-51.
25. Wang X, He B, Shi J, Li Q, Zhu HJ. Comparative Proteomics Analysis
of Human Liver Microsomes and S9 Fractions. Drug Metab Dispos.2020;48(1):31-40.
26. Sai Y, Dai R, Yang TJ, et al. Assessment of specificity of eight
chemical inhibitors using cDNA-expressed cytochromes P450.Xenobiotica; the fate of foreign compounds in biological systems.2000;30(4):327-43.
27. Ching MS, Blake CL, Malek NA, Angus PW, Ghabrial H. Differential
inhibition of human CYP1A1 and CYP1A2 by quinidine and quinine.Xenobiotica; the fate of foreign compounds in biological systems.2001;31(11):757-67.
28. Naraharisetti SB, Lin YS, Rieder MJ, et al. Human liver expression
of CYP2C8: gender, age, and genotype effects. Drug Metab Dispos.2010;38(6):889-93.
29. Wu S, Moomaw CR, Tomer KB, Falck JR, Zeldin DC. Molecular cloning
and expression of CYP2J2, a human cytochrome P450 arachidonic acid
epoxygenase highly expressed in heart. J Biol Chem.1996;271(7):3460-8.
30. Michaud V, Frappier M, Dumas MC, Turgeon J. Metabolic activity and
mRNA levels of human cardiac CYP450s involved in drug metabolism.PLoS One. 2010;5(12):e15666.
31. Delozier TC, Kissling GE, Coulter SJ, et al. Detection of human
CYP2C8, CYP2C9, and CYP2J2 in cardiovascular tissues. Drug Metab
Dispos. 2007;35(4):682-8.
32. Node K, Huo Y, Ruan X, et al. Anti-inflammatory properties of
cytochrome P450 epoxygenase-derived eicosanoids. Science.1999;285(5431):1276-9.
33. Xu X, Zhang XA, Wang DW. The roles of CYP450 epoxygenases and
metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant
diseases. Adv Drug Deliv Rev. 2011;63(8):597-609.
34. Cheong EJ, Goh JJ, Hong Y, et al. Application of Static Modeling
–in the Prediction of In Vivo Drug-Drug Interactions between
Rivaroxaban and Antiarrhythmic Agents Based on In Vitro Inhibition
Studies. Drug Metab Dispos. 2017;45(3):260-8.
Table
1 . Kinetic parameters of rivaroxaban by HLM and selected CYPs.